← Hemab Therapeutics Holdings, Inc. (COAG) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Hemab Therapeutics Holdings, Inc. (COAG)
Biological Products, (No Diagnostic Substances) · market cap $1.7B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-10 (est.)
Earnings
Pipeline
3
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotech with 59 employees and a ~$2.3B market cap focused on rare bleeding disorders. Its pipeline comprises three Phase 2 assets — sutacimig (Congenital Factor VII Deficiency), HMB-002 (Von Willebrand Disease), and HMB-001 (Glanzmann Thrombasthenia) — none of which have reported topline Phase 2 data yet. With only ~$49.9M cash and a 6.9-month runway, the company faces near-term financing pressure ahead of any meaningful data readouts.
The catalyst path
- 2026-11-10 (est.)Earningsimp 5/10
- 2027-07-15 (est.)Phase 2 · HMB-002 (Part A)imp 7/10
- 2027-08-15 (est.)Phase 2 · HMB-001imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Sutacimig | Phase 2 | Congenital Factor VII Deficiency |
| HMB-002 (Part A) | Phase 2 | Von Willebrand Disease (VWD) |
| HMB-001 | Phase 2 | Glanzmann Thrombasthenia |
Price & technical context
3-month
+0.2%
6-month
—
12-month
—
52-wk range
$24.98–$54.94
vs 50-day MA
-30.7%
vs 200-day MA
—
Realized vol
91.5%
Max drawdown
-43.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for COAG (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.